Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
IPO Year:
Exchange: NYSE
Website: tevapharm.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2025 | $35.00 | Overweight | Barclays |
| 12/5/2025 | $35.00 | Sector Outperform | Scotiabank |
| 6/6/2025 | $24.00 | Buy | Goldman |
| 5/28/2025 | $25.00 | Buy | Truist |
| 5/12/2025 | $23.00 | Neutral → Overweight | Analyst |
| 7/10/2024 | $20.00 | Hold → Buy | Argus |
| 3/8/2024 | $14.00 | Underweight → Neutral | JP Morgan |
| 2/12/2024 | $12.00 → $19.00 | Neutral → Overweight | Piper Sandler |
| 1/23/2024 | $10.00 → $14.00 | Hold → Buy | Jefferies |
| 1/3/2024 | $8.00 → $12.00 | Underweight → Neutral | Piper Sandler |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Barclays initiated coverage of Teva Pharma with a rating of Overweight and set a new price target of $35.00
Scotiabank initiated coverage of Teva Pharma with a rating of Sector Outperform and set a new price target of $35.00
Goldman initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $24.00
Truist initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $25.00
Analyst upgraded Teva Pharma from Neutral to Overweight and set a new price target of $23.00
Argus upgraded Teva Pharma from Hold to Buy and set a new price target of $20.00
JP Morgan upgraded Teva Pharma from Underweight to Neutral and set a new price target of $14.00
Piper Sandler upgraded Teva Pharma from Neutral to Overweight and set a new price target of $19.00 from $12.00 previously
Jefferies upgraded Teva Pharma from Hold to Buy and set a new price target of $14.00 from $10.00 previously
Piper Sandler upgraded Teva Pharma from Underweight to Neutral and set a new price target of $12.00 from $8.00 previously
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
10-Q - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
DEFA14A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
DEF 14A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
144 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
10-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
Fastest customizable press release news feed in the world
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations. Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE:AND) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimi
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. TEL AVIV, Israel and ZUG, Switzerland, July 09, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE:AND) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commerci
TORONTO, Canada and INCHEON, South Korea, July 9, 2026 /CNW/ - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE: TEVA) and Samsung Bioepis Co., Ltd. today announced that the companies have entered into a license and commercialization agreement for OPUVIZ® (aflibercept), a biosimilar referencing Eylea®1 (aflibercept), in Canada. Under the agreement, Samsung Bioepis is responsible for registration and manufacture of the products, while Teva Canada (a subsidiary of Teva Pharmaceutical Industries Ltd.) is responsible for commercialization."This agreement is an important step in strengthening our biosimilars portfolio in Canada
Teva-discovered TEV-’408 targets IL-15, a key driver of vitiligo biology TEV-’408 showed improvement in skin pigmentation and was well-tolerated with no safety signals observed to dateNearly 75% of patients reported improvement in facial vitiligo, with half reporting "much’ or "very much" improvedTEV-’408 is designed for convenient quarterly (Q12W) subcutaneous dosing Teva will hold an investor call and live webcast today,Tuesday, July 7, 2026, at 8:00 a.m. ET to discuss these data. TEL AVIV, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to advance its TEV-’408, an investigational anti-interleukin-15 monoclonal
TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2026 Aide Memoire is available on the "Investors" page on its website. Q2 2026 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of second quarter 2026 results, which are expected to be released on Wednesday, July 29, 2026, at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET on the same day. This document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Tev
NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designationsEcopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved. TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for the treatment of pediatric Tourette syndr
TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2026 financial results on Wednesday, July 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be
Ecopipam, an investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations. The acquisition expands Teva's innovative pipeline in a specialized area of neuroscience with significant unmet need and is expected to support near- and long-term growth. At closing, Teva paid $700 million consideration with the potential for up to an additional $200 million in commercial milestone payments, as well as net sales-based royalties, upon commercialization and subject to regulatory approval. TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva P
New analysis from the IMPACT-TD Registry demonstrates that treatment with AUSTEDO and AUSTEDO XR led to reductions in Abnormal Involuntary Movement Scale (AIMS) scores in all participants, which were associated with improved activities of daily living.Further data from the 3-year RIM-TD study reinforces the importance of sustained treatment, showing >50% of patients achieve a clinically meaningful response to AUSTEDO by week 15, with additional patients achieving response with continued treatment.The comprehensive data package presented at Psych Congress Elevate advances clinical understanding of TD from diagnosis to long-term management, underscoring Teva's commitment to improving outcomes
New real-world survey data reveal the daily impact of Huntington's disease (HD) chorea, with over 68% of patients reporting interference with social life or emotional wellbeing1 and up to 83% of caregivers noting impact on their own daily lives.2Following treatment with AUSTEDO or AUSTEDO XR, most patients (60-71%) reported improvement across multiple quality of life domains as a result of their improved movements.1 As a result of the patient's reduced chorea impact, most caregivers reported less impact to their daily lives.2These real-world findings reinforce Teva's commitment to advancing innovative treatment options that improve the lives of individuals living with HD chorea and their car
Live Leadership Updates
First cohort features 7 real-world challenges across R&D, manufacturing and supply chain, commercial and medical affairs Teva's first-ever global innovation platform aims to accelerate patient impact and drive business transformation, as part of its Pivot to Growth StrategyRise will enable startups and tech players worldwide to validate their solutions in real-world settings, scaling impact across Teva's global ecosystem including in the U.S., Europe, Israel and beyond TEL AVIV, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today unveiled Teva Rise, a global open innovation platform designed to harness the power of a variety of disruptive tech
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company's manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva's Executive Leadership Team and report directly to President and CEO Richard Francis. He will be based in Teva's U.S. headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api). Dr. Ananth will lead the API business starting November 27, 2023, and will be based out of Teva's U.S. headquarters in Parsippany, NJ. Richard Francis, Teva's President and CEO said: "I am excited to welcome Ananth back to Teva to lead the Teva api business during this pivotal time for our company, as we continue to progress on our plan for turning Teva api into a standalone business. We're confident that this strategy will result in a more focused end-to-end operation, and I am confident tha
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced changes to its leadership team. Sven Dethlefs, Executive Vice President, North America Commercial, will leave Teva on November 17, 2023, and Christine (Chris) Fox, who most recently served as Global President, Gene Therapies at Novartis will be the new head of Teva's U.S. Commercial Business. "On behalf of the Teva Board of Directors and our executive management team, I want to thank Sven for his many contributions to Teva during his 15 years with the company," said Richard Francis, Teva's President, and Chief Executive Officer, "I am pleased to announce the appointment of Chris Fox to this critical role. Chris is a h
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. Angus Grant, Ph.D., as EVP, Business Development. Dr. Grant will begin his employment on August 1, 2023, and will be based out of Teva's US headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230727524382/en/(Photo: Business Wire) Dr. Grant joins Teva with over 25 years of experience in the global pharmaceutical and biotech industry, with an exceptional track record across a variety of fields including Business Development, R&D and Regulatory Affairs. Most recently, Dr. Grant served as the Chief Business Ex
Kåre Schultz to Retire After a Transformative Five-Year Tenure Setting the Stage for an Exciting Future Teva Pharmaceutical Industries Ltd. ("Teva" or the "Company") (NYSE and TASE: TEVA), today announced that the Company's Board of Directors has appointed Richard Francis as President and Chief Executive Officer, effective January 1, 2023. In order to facilitate an orderly transition, Kåre Schultz and the Teva Board of Directors have mutually agreed that Mr. Schultz will retire from his current position as Chief Executive Officer, effective December 31, 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121005362/en/ Mr. Fr
SHANGHAI, Oct. 31, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Sylvie Peltier ("Dr. Peltier") has been appointed as Senior Vice President of Global Regulatory Affairs of the Company with effect from October 31st, 2022. She will be responsible for developing global regulatory strategies, leading and driving the Company's regulatory affairs activities, and initiatives in support of IND/CTA/BLA filing and approval of developmental products globally. Dr. Peltier has extensive global leadership and hands-on experiences in cl
PRINCETON, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective July 21, 2022. Her appointment brings the company's board of directors to eleven members. "We are excited to welcome an accomplished business leader with a proven track record of success join Certara's Board," said William F. Feehery, PhD, CEO of Certara. "Rose's experience in executive leadership and expertise in commercialization will provide immense value as the Company grows its impact on the biopharmaceutical industry worldwide." Ms. Crane has more than 35 years of experience in the ph
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the appointment of Eric A. Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Dr. Hughes will begin his employment on August 1, 2022, and will be based out of Teva's U.S. headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220701005225/en/(Photo: Business Wire) Dr. Hughes joins Teva with nearly 20 years of experience in all phases of drug development in leading global pharmaceutical companies, most recently as Senior Vice President of Clinical Development and Translational Medicine at Vertex Pharmac
Live finance-specific insights
TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2026 Aide Memoire is available on the "Investors" page on its website. Q2 2026 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of second quarter 2026 results, which are expected to be released on Wednesday, July 29, 2026, at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET on the same day. This document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Tev
TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2026 financial results on Wednesday, July 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be
For an accessible version of this Press Release, please visit www.tevapharm.com Q1 2026 revenues of ~$4.0 billion increased by 2% in U.S. dollars year-over-year (YoY), and decreased by 3% in local currency terms (LC). Excluding the Japan business venture (BV) results, revenues decreased by 1% in LC. These strong first quarter results were driven by our innovative portfolio growth and disciplined execution, even with lower revenues from lenalidomide capsules (the generic version of Revlimid®) due to increased generic competition in the U.S.Key Innovative brands continued to drive growth and provide value for patients, while transforming Teva's portfolio mix and financial profile: AUSTEDO®
TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the "Investors" page on its website. Q1 2026 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of first quarter 2026 results, which are expected to be released on Wednesday, April 29, 2026 at 7am ET, followed by a conference call at 8am ET. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Indust
TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC.Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 billion, +35% YoY in LC: AUSTEDO® global revenues of $2.26 billion, growing 34% YoY in LC. AJOVY® global revenues of $673 million, up 30% YoY in LC.UZEDY® revenues of $191 million, up 63% YoY in LC; underscoring Teva's commitment to drive new advances in neuroscience: Fastest growing long-acting injectable (LAI)1FDA expanded indicati
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-‘408TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva's Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (NASDAQ:RPRX), today announced a funding agreement of up to $500 million to accel
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the "Investors" page on its website. Q4 2025 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of fourth quarter 2025 results, which are expected to be released on Wednesday, January 28, 2026 at 7am ET, followed by a conference call at 8am ET. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Indu
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday, January 28, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be available within 2
For an accessible version of this Press Release, please visit www.tevapharm.com Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues increased 5% in U.S. dollars or 3% in LC. United States segment increased by 12%; Europe segment decreased by 10% in LC; and International Markets segment decreased by 10% in LC, or increased by 2% in LC excluding Japan BV in Q3 2024, all compared to the third quarter of 2024.GAAP operating income margin of 19.7% and non-GAAP operating income margin of 28.9% (+86 bps YoY), driven by our key innovative brands' growth. On tr
This live feed shows all institutional transactions in real time.
SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)